Cargando…

Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus

Hepatitis E virus (HEV), rotavirus (RV), and astrovirus (AstV) are important pathogens that transmit through a common fecal-oral route, causing hepatitis (HEV) and gastroenteritis (RV and AstV) respectively in humans. In this study, we developed and evaluated two subunit vaccine candidates that cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Ming, Wei, Chao, Wang, Leyi, Cao, Dianjun, Meng, Xiang-Jin, Jiang, Xi, Tan, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872161/
https://www.ncbi.nlm.nih.gov/pubmed/27194006
http://dx.doi.org/10.1038/srep25735
_version_ 1782432692029095936
author Xia, Ming
Wei, Chao
Wang, Leyi
Cao, Dianjun
Meng, Xiang-Jin
Jiang, Xi
Tan, Ming
author_facet Xia, Ming
Wei, Chao
Wang, Leyi
Cao, Dianjun
Meng, Xiang-Jin
Jiang, Xi
Tan, Ming
author_sort Xia, Ming
collection PubMed
description Hepatitis E virus (HEV), rotavirus (RV), and astrovirus (AstV) are important pathogens that transmit through a common fecal-oral route, causing hepatitis (HEV) and gastroenteritis (RV and AstV) respectively in humans. In this study, we developed and evaluated two subunit vaccine candidates that consisted of the same protruding or spike protein antigens of the three viruses in two formats, a fusion of the three antigens into one molecule (fused vaccine) vs. a mixture of the three free antigens together (mixed vaccine). Both vaccines were easily made via E. coli expression system. Mouse immunization experiments showed that the fused vaccine elicited significantly higher antibody responses against the three viral antigens than those induced by the mixed vaccine. In addition, the mouse post-immune antisera of the fused vaccine revealed significantly higher neutralizing titers against HEV infection in cell culture, as well as significantly higher 50% blocking titers (BT(50)) against RV VP8-HBGA receptor interactions than those of the post-immune antisera after immunization of the mixed vaccine. Thus, the fused vaccine is a promising trivalent vaccine candidate against HEV, RV, and AstV, which is worth for further development.
format Online
Article
Text
id pubmed-4872161
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48721612016-06-01 Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus Xia, Ming Wei, Chao Wang, Leyi Cao, Dianjun Meng, Xiang-Jin Jiang, Xi Tan, Ming Sci Rep Article Hepatitis E virus (HEV), rotavirus (RV), and astrovirus (AstV) are important pathogens that transmit through a common fecal-oral route, causing hepatitis (HEV) and gastroenteritis (RV and AstV) respectively in humans. In this study, we developed and evaluated two subunit vaccine candidates that consisted of the same protruding or spike protein antigens of the three viruses in two formats, a fusion of the three antigens into one molecule (fused vaccine) vs. a mixture of the three free antigens together (mixed vaccine). Both vaccines were easily made via E. coli expression system. Mouse immunization experiments showed that the fused vaccine elicited significantly higher antibody responses against the three viral antigens than those induced by the mixed vaccine. In addition, the mouse post-immune antisera of the fused vaccine revealed significantly higher neutralizing titers against HEV infection in cell culture, as well as significantly higher 50% blocking titers (BT(50)) against RV VP8-HBGA receptor interactions than those of the post-immune antisera after immunization of the mixed vaccine. Thus, the fused vaccine is a promising trivalent vaccine candidate against HEV, RV, and AstV, which is worth for further development. Nature Publishing Group 2016-05-19 /pmc/articles/PMC4872161/ /pubmed/27194006 http://dx.doi.org/10.1038/srep25735 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Xia, Ming
Wei, Chao
Wang, Leyi
Cao, Dianjun
Meng, Xiang-Jin
Jiang, Xi
Tan, Ming
Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus
title Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus
title_full Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus
title_fullStr Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus
title_full_unstemmed Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus
title_short Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus
title_sort development and evaluation of two subunit vaccine candidates containing antigens of hepatitis e virus, rotavirus, and astrovirus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872161/
https://www.ncbi.nlm.nih.gov/pubmed/27194006
http://dx.doi.org/10.1038/srep25735
work_keys_str_mv AT xiaming developmentandevaluationoftwosubunitvaccinecandidatescontainingantigensofhepatitisevirusrotavirusandastrovirus
AT weichao developmentandevaluationoftwosubunitvaccinecandidatescontainingantigensofhepatitisevirusrotavirusandastrovirus
AT wangleyi developmentandevaluationoftwosubunitvaccinecandidatescontainingantigensofhepatitisevirusrotavirusandastrovirus
AT caodianjun developmentandevaluationoftwosubunitvaccinecandidatescontainingantigensofhepatitisevirusrotavirusandastrovirus
AT mengxiangjin developmentandevaluationoftwosubunitvaccinecandidatescontainingantigensofhepatitisevirusrotavirusandastrovirus
AT jiangxi developmentandevaluationoftwosubunitvaccinecandidatescontainingantigensofhepatitisevirusrotavirusandastrovirus
AT tanming developmentandevaluationoftwosubunitvaccinecandidatescontainingantigensofhepatitisevirusrotavirusandastrovirus